ArticleTheranostics2019
Orally Deliverable Nanotherapeutics for the Synergistic Treatment of Colitis-Associated Colorectal Cancer.
Article in Theranostics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed.
- In situ sol-gel-sol transformation formed by sodium alginate realizes folic acid-modified chitosan nanoparticles to deliver hops β-acids for colorectal cancer therapy.Journal of nanobiotechnology · 2026Article
- Review
- Gut microbiota and macrophage crosstalk: implications for colitis-associated colorectal cancer.Frontiers in cellular and infection microbiology · 2026Review
- The role of extracellular vesicles in the transport and regulation of novel inflammatory mediators in IBD and its associated CRC.Frontiers in cell and developmental biology · 2026Review
- Nanomedicine for Oral Delivery: Strategies to Overcome the Biological Barriers.Small methods · 2026Review
- Integrative green synthesis and molecular simulation of ibrutinib cocrystals for enhanced biopharmaceutical performance and in vivo pharmacokinetics.International journal of pharmaceutics: X · 2025Article
- Reduction of colitis in mice by chemically programmed supramolecular nanoassemblies of vitamin-lipid conjugates.Journal of nanobiotechnology · 2025Article
- Classification of Nanomaterial Drug Delivery Systems for Inflammatory Bowel Disease.International journal of nanomedicine · 2025Review
- Article
- Identification of PFKFB3 as a key factor in the development of colorectal cancer and immunotherapy resistance.Clinical and experimental medicine · 2024Article
- Nanomaterials modulate tumor-associated macrophages for the treatment of digestive system tumors.Bioactive materials · 2024Review
- Advancing Polyphenol-Based Nanomedicine for Inflammatory Bowel Disease: Challenges and Opportunities.Journal of inflammation research · 2024Review
- Research Advances of Lipid Nanoparticles in the Treatment of Colorectal Cancer.International journal of nanomedicine · 2024Review
- Oral liposomal delivery of an activatable budesonide prodrug reduces colitis in experimental mice.Drug delivery · 2023Article
- Designing a microbial fermentation-functionalized alginate microsphere for targeted release of 5-ASA using nano dietary fiber carrier for inflammatory bowel disease treatment.Journal of nanobiotechnology · 2023Article
- Article
- Theranostics Nanomedicine Applications for Colorectal Cancer and Metastasis: Recent Advances.International journal of molecular sciences · 2023Review
- Catechins: Protective mechanism of antioxidant stress in atherosclerosis.Frontiers in pharmacology · 2023Review
- Development of an Oral Isoliquiritigenin Self-Nano-Emulsifying Drug Delivery System (ILQ-SNEDDS) for Effective Treatment of Eosinophilic Esophagitis Induced by Food Allergy.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Nanoparticles Loaded with Platinum Drugs for Colorectal Cancer Therapy.International journal of molecular sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.